Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danoprevir/Ritonavir and Mericitabine Combinations in Treatment-Experienced HCV Genotype 1
NCT01331850Phase 2Completed
- Sponsor
- Roche
- Start
- May 2011
- Primary completion
- Jan 2013
- Modality
- Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 2 trial of danoprevir in hepatitis C (HCV), sponsored by Roche. Started May 2011; status: completed.
02
Drugs
danoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01331850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01331850.